Rectal Suppository of Mucoadhesive Microspheres of Alverine Citrate for İrritable Bowel Disease: In vitro Evaluation
[...]it is not administered by parenteral route due to pain and safety issues. [...]rectal administration of medicaments is preferable due to the advantages that include: a) improved enzymatic drug stability b) higher drug content c) constant and static environment of rectum d) avoidance of overdosi...
Gespeichert in:
Veröffentlicht in: | Research journal of pharmacy and technology 2018-07, Vol.11 (7), p.3091-3098 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [...]it is not administered by parenteral route due to pain and safety issues. [...]rectal administration of medicaments is preferable due to the advantages that include: a) improved enzymatic drug stability b) higher drug content c) constant and static environment of rectum d) avoidance of overdosing e) improved patient compliance f) avoidance of first pass effect in the gastrointestinal tract and liver.Conventional solid suppositories have variousdisadvantages such as patient feels a discomfort due to its solid nature7,8. Drug diffusion from chitosan microspheres may be controlled by cross linking with a dialdehyde such as glutaraldehyde12.If such mucoadhesive microspheres containing chitosan loaded with alverine citrate are developed, drug will adhere to the rectal mucosa and will absorb from lower hemorrhoidal veins and may increase the bioavailability10. [...]present investigation aims to formulate mucoadhesive microspheres of ALV for rectal delivery that may be useful to relieve the symptoms of IBS. [...]of this degree of freedom and degree of entanglement was decreased. Combination of 4000 PEG and PEG 2000 showed more water solubility than single PEG bases. [...]it is concluded that combination of PEG 4000 and PEG 2000 (1:1.5) in the formulation enhanced the drug release.The release kinetics from different suppository formulations is shown in table 6. |
---|---|
ISSN: | 0974-3618 0974-360X 0974-306X |
DOI: | 10.5958/0974-360X.2018.00568.1 |